News | June 17, 2008

PET Detects “Silent Heart” Stage in Asymptomatic Diabetic Patients

June 18, 2008 - Researchers using positron emission tomography (PET) are able to see changes in coronary blood vessels, offering hope that those at risk of cardiac deaths caused by disease in the heart’s vessels can receive earlier treatment and prolong life.

As many as 50 percent of all cardiac deaths due to disease in the heart’s vessels occur in individuals with no prior history or symptoms of heart disease. In addition, standard coronary risk factors may fail to explain up to 50 percent of cardiovascular events.

“Assessment of standard coronary risk factors such as arterial hypertension, smoking, hypercholesterolemia or diabetes appears to be limited in defining an individual’s future cardiac risk,” said Thomas Schindler, M.D., chief of nuclear cardiology at the University Hospitals of Geneva, Geneva, Switzerland.
Early stages of atherosclerosis (a disease affecting arterial blood vessels) can be detected by different cardiovascular imaging techniques, he explained. For example, intravascular ultrasound may identify abnormal thickening of the subintimal space (below the inner layer of blood vessels) of the carotid artery as an early sign of developing arterial disease, electron-beam or multi-detector computed tomography (MDCT) may identify calcification of the heart vessels and PET may detect functional abnormalities of the coronary arteries by unmasking mild reductions in the blood flow supply to the heart during stress testing.
Notably, the identification of abnormal thickening of the arterial wall of the carotid with intravascular ultrasound, coronary artery calcifications with MDCT and functional abnormalities of the coronary circulation with PET have all been shown to identify the initiation and development of atherosclerotic disease of the heart vessels and future cardiovascular events such as myocardial infarction, sudden cardiac death, heart failure or the need for revascularization procedures (restoring the circulatory structures) for the heart.
“These measures to detect clinically silent heart vessel disease may be more useful in defining the future cardiac risk in individuals than conventional coronary risk factor assessment and could thereby better reinforce the preventive therapy for improving the long-term cardiovascular outcome,” said Dr. Schindler.
The difficulty is, he added, that it is not known which of these markers of subclinical heart vessel disease is first to manifest.
In a study of 68 asymptomatic individuals with type 2 diabetes (or adult onset diabetes), researchers were able to determine the concurrent prevalence of the thickening in arterials walls (carotid-intima media thickness, IMT), coronary artery calcification (CAC) and functional abnormalities of the coronary circulation (coronary vascular dysfunction). In these patients—all of whom had coronary vascular dysfunction as determined by PET scans—a 56 percent increase in the prevalence of abnormal carotid IMT was found, while 66 percent also had evidence of CAC.
The results showed that when PET revealed coronary vascular dysfunction as a functional precursor of coronary artery disease, these findings were not necessarily accompanied by abnormal increases in the carotid IMT or CAC, leading researchers to believe that the dysfunction may precede structural alterations of the arterial wall.
“PET assessment of functional abnormalities of the coronary circulation, therefore, may allow the earliest identification of developing heart vessel disease. This could lead to an optimized identification of the very early stage of the development of coronary artery disease, allowing physicians to initiate and/or reinforce preventive medical therapy strategies in order to improve the long-term cardiovascular outcome in these individuals at risk for heart disease,” said Dr. Schindler.
Heart disease is one of the complications of type 2 diabetes. According to the American Heart Association, more than 80 million people in the United States have one or more forms of cardiovascular disease.

Scientific Paper 300: T. H. Schindler, V. M. Gabriella, R. Nkoulou and O. Ratib, Internal Medicine, Nuclear Cardiology and Cardiovascular Center, Geneva, Geneva, Switzerland; J. Goldin and H. R. Schelbert, Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, Calif., “Carotid Intima-media Thickness, Coronary Artery Calcification and Coronary Vasomotion in Asymoptomatic Type 2 Diabetic Patients,” SNM 55th Annual Meeting, June 14–18, 2008.

For more information: www.snm.org

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

News | PET-CT | June 09, 2017
Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Overlay Init